Analysts Say Turning Point Therapeutics Inc. (NASDAQ:TPTX) Can Really Get To $175.00 In 12 Months – Marketing Sentinel
Home  »  Company   »  Analysts Say Turning Point Therapeutics Inc. (NASD...

Analysts Say Turning Point Therapeutics Inc. (NASDAQ:TPTX) Can Really Get To $175.00 In 12 Months

In last trading session, Turning Point Therapeutics Inc. (NASDAQ:TPTX) saw 0.76 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $38.34 trading at $3.32 or 9.48% at ring of the bell on the day assigns it a market valuation of $1.99B. That closing price of TPTX’s stock is at a discount of -268.54% from its 52-week high price of $141.30 and is indicating a premium of 9.81% from its 52-week low price of $34.58. Taking a look at company’s average trading volume of 485.57K if we extend that period to 3-months.

For Turning Point Therapeutics Inc. (TPTX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.39 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Turning Point Therapeutics Inc. (NASDAQ:TPTX) trade information

Upright in the green during last session for gaining 9.48%, in the last five days TPTX remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $38.34 price level, adding 11.6% to its value on the day. Turning Point Therapeutics Inc.’s shares saw a change of -19.62% in year-to-date performance and have moved -10.73% in past 5-day. Turning Point Therapeutics Inc. (NASDAQ:TPTX) showed a performance of -6.21% in past 30-days.

Wall Street analysts have assigned a consensus price target of $127.11 to the stock, which implies a rise of 69.84% to its current value. Analysts have been projecting $50.00 as a low price target for the stock while placing it at a high target of $175.00. It follows that stock’s current price would drop -356.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -30.41% for stock’s current value.

Turning Point Therapeutics Inc. (TPTX) estimates and forecasts

Statistics highlight that Turning Point Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -42.84% of value to its shares in past 6 months, showing an annual growth rate of -20.00% while that of industry is 16.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -36.30% in the current quarter and calculating -80.80% decrease in the next quarter. This year revenue growth is estimated to rise 23.70% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $110k for the same.

TPTX Dividends

Turning Point Therapeutics Inc. is more likely to be releasing its next quarterly report between February 28 and March 04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Turning Point Therapeutics Inc. (NASDAQ:TPTX)’s Major holders

Insiders are in possession of 3.68% of company’s total shares while institution are holding 97.83 percent of that, with stock having share float percentage of 101.56%. Investors also watch the number of corporate investors in a company very closely, which is 97.83% institutions for Turning Point Therapeutics Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at TPTX for having 3.87 million shares of worth $256.91 million. And as of Sep 29, 2021, it was holding 7.82% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 3.75 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 7.58% of outstanding shares, having a total worth of $249.16 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

On the other hand, Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 1.3 million shares of worth $53.9 million or 2.62% of the total outstanding shares. The later fund manager was in possession of 1.13 million shares on Sep 29, 2021, making its stake of worth around $74.92 million in the company or a holder of 2.28% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts



Download Free eBook For



100% free. stop anytime no spam